Brand-name drug · growth hormone-releasing factor (GHRF) analog
Egrifta (tesamorelin)
From the FDA label, read Published by PepVault
Egrifta is tesamorelin from Theratechnologies, a daily injection that acts like the body’s own signal for releasing growth hormone; it is sold today as Egrifta SV and Egrifta WR.
FDA approved it for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy, a change in how the body stores fat.
- Active ingredient
- Tesamorelin
- Maker
- Theratechnologies
- Class
- growth hormone-releasing factor (GHRF) analog
- FDA application
- BLA 022505, first approved 2010
What FDA approved it for
The label is explicit about what Egrifta is not: it is not a weight-loss medicine, because its effect on weight is neutral, and its long-term heart safety has not been established. It also notes no evidence that it helps people keep to their HIV medicines.
For someone who hasn’t lost belly fat on it, the label asks the prescriber to weigh whether to continue.
From the label: 2.1 Recommended Dosage and Administration Instructions; 1 Indications and Usage.
How it is supplied
| Form | Doses |
|---|---|
| Egrifta SV vial (powder) | 2 mg per vial |
| Egrifta WR vial (powder) | 11.6 mg per vial |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Egrifta SV, once a day
| Dose | When, on the label |
|---|---|
| 1.4 mg a day | Every day |
Egrifta WR, once a day
| Dose | When, on the label |
|---|---|
| 1.28 mg a day | Every day |
Egrifta has no climb: each form is one dose a day from the start. Egrifta WR’s 1.28 mg and Egrifta SV’s dose differ because the formulations differ, which is why the label says one can’t stand in for the other.
From the label: 2.1 Dosage and Administration; 2.1 Recommended Dosage and Administration Instructions.
How it’s taken
Both forms are powders mixed with the water that comes in the box, then injected under the skin of the belly once a day, moving around the belly and avoiding scars, bruises and the navel.
The two forms are not interchangeable. Egrifta SV is mixed fresh for each daily dose and used at once; one mixed Egrifta WR vial covers 7 days in a row and is thrown away 7 days after mixing.
From the label: 2.1 Recommended Dosage and Administration Instructions; 2.2 Reconstitution Procedure.

If a dose is missed
Egrifta’s label gives no instruction for a missed dose; a prescriber or pharmacist can answer for a given case.
Storage
Unmixed vials of either form are kept at room temperature, 68°F to 77°F, in the original box away from light.
A mixed Egrifta WR vial also stays at room temperature and is never frozen; a mixed Egrifta SV dose is used straight away, not kept in the fridge.
From the label: 16 How Supplied/Storage and Handling; 2.2 Reconstitution Procedure.
Side effects and warnings
| Reaction | Placebo | Egrifta |
|---|---|---|
| Injection site reaction | 6 | 17 |
| Joint pain (arthralgia) | 11 | 13 |
| Pain in arms or legs | 5 | 6 |
| Muscle pain (myalgia) | 2 | 6 |
| Swelling of the legs or feet | 2 | 6 |
| Tingling (paresthesia) | 2 | 5 |
| Reduced feeling (hypoesthesia) | 2 | 4 |
| Rash | 2 | 4 |
The pooled trials gave Egrifta to 543 people and placebo to 263; reactions where the shot goes in were the most common, in 17% against 6%.
The other warnings
Egrifta has no boxed warning. Its warnings cover a possible risk of cancer growth (it raises growth hormone and IGF-1, so the label rules it out with active cancer), raised IGF-1 levels, fluid retention, higher blood sugar or diabetes, allergic reactions, reactions at the injection site, and a higher risk of death in people who are acutely critically ill. It must not be used in pregnancy or with a disrupted hypothalamic-pituitary axis.
From the label: 6.1 Clinical Trials Experience; 5 Warnings and Precautions.
What else we have on tesamorelin
Tesamorelin on PepVault
Free tools
The trials, in plain English
- Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIV
- Tesamorelin: visceral fat down 18% over 52 weeks in HIV patients
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeks
- Tesamorelin cut visceral and liver fat over 6 months in HIV patients
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy
Compound against compound
Questions about Egrifta
What is the dose of Egrifta?
One dose a day, injected into the belly: 1.4 mg for Egrifta SV, or 1.28 mg for Egrifta WR. The two forms are not interchangeable. A prescriber sets the dose.
Is Egrifta a weight-loss drug?
No. Its label approves it only for reducing excess belly fat in adults with HIV and lipodystrophy, and says it is not for weight loss because its effect on weight is neutral.
What is the difference between Egrifta SV and Egrifta WR?
Egrifta SV comes as a 2 mg vial mixed fresh for each 1.4 mg daily dose. Egrifta WR comes as an 11.6 mg vial; once mixed, it gives daily 1.28 mg doses for 7 days.
How is Egrifta stored?
The unmixed vials stay at room temperature, 68°F to 77°F, in the original box away from light.
Sources
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, FDA label on DailyMed (version 2, published Aug 3, 2026; read Nov 18, 2026)
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use, FDA label on DailyMed (version 9, published Jul 31, 2026; read Nov 18, 2026)
- Drugs@FDA, BLA 022505 (Egrifta, Egrifta SV and Egrifta WR; application first approved 2010)
PepVault is not affiliated with Theratechnologies. Egrifta is a trademark of its owner.